« Intensity en el Nuevo Gold Standard de Lentes Multifocales. Mi Experiencia en 500 Pacientes » by Dr. Germán Bianchi

In July 2025, Hanita Korea welcomed over 40 ophthalmologists to the Intensity IOL Symposium at Josun Palace, Gangnam, Seoul. The event featured two distinguished lectures: – Prof. Gerd U. Auffarth (Heidelberg University Hospital) presented clinical data and findings from a prospective randomized controlled trial of the Intensity IOL. – Prof. Seung Pil Bang (Keimyung University Dongsan Hospital), the first Korean ophthalmologist to earn a Ph.D. in optical science from the

In July 2025, Hanita Korea hosted the Intensity IOL Symposium at the Westin Josun Busan, welcoming leading ophthalmologists to share insights and real-world experiences with the Intensity Pentafocal IOL. The symposium featured expert presentations from Prof. Gerd U. Auffarth (Heidelberg University Hospital), Dr. Jiwon Jeong (Fatima Eye Clinic), and Dr. Junhun Lee (i-Back Eye Center). Speakers highlighted the innovative optical design and strong clinical performance of Intensity, emphasizing its ability

In July 2025, Hanita Korea held the inaugural Intensity IOL Symposium in Daegu. Chaired by Prof. Hong Kyun Kim (Kyungpook National University Hospital), the symposium featured expert lectures from Prof. Gerd U. Auffarth (Heidelberg University Hospital), Dr. Junhun Lee (i-Back Eye Center), and Prof. Jonghwa Jun (Keimyung University Dongsan Medical Center). The discussions highlighted the unique pentafocal design of the Intensity IOL, demonstrating its ability to provide excellent vision across

In his DOC 2025 presentation, Raphael Neuhann, FEBO shares his firsthand experience using the Intensity Pentafocal IOL. He reports excellent uncorrected visual acuity, strong contrast sensitivity under low-light conditions, and a very low enhancement rate of just 1.2%. With smooth vision transitions and rapid neuroadaptation, Intensity outperforms traditional trifocals in functional, real-world vision. Dr. Neuhann now considers it his go-to choice for patients seeking full spectacle independence.